Pharma Stocks in the News: Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Myriad Genetics, Inc. (NASDAQ:MYGN)

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) reported a larger-than-expected Q3 loss Monday, but shares rose as the biotechnology company also unveiled plans to release new data next Friday from a phase 1/2 trial evaluating the combination of TH-302 and Avastin (bevacizumab) in patients with bevacizumab-refractory recurrent glioblastoma. Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) was up 3.8% at $3.04 in recent trading shortly after the open, although that is near the lower end of its 52-week range between $2.82 and $5.93.The company reported a net loss of $7.75 million, or $0.15 per diluted share, compared with a profit of $1.2 million, or a loss of $0.08 per diluted share. The loss included a $7.6 million operating loss and non-cash expense of $0.3 million related to changes in fair value of outstanding and exercised warrants. Analysts were expecting a loss of $0.11 per share on a GAAP basis, according to Capital IQ. Revenue in the quarter was $3.7 million, in line with the Street view. The revenue was up from $3.2 million a year earlier, as it recognized revenue from the amortization of the aggregate of $110 million in upfront payment and milestone payments that were earned in 2013 and 2012 from a global license and co-development agreement for TH-302 with Germany's Merck KGaA.Separately, the company said new data from an investigator-sponsored phase 1/2 trial evaluating the combination of TH-302 and Avastin (bevacizumab) in patients with bevacizumab-refractory recurrent glioblastoma will be presented at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology to be held in Miami from Nov. 13 to Nov. 16. The company will have two poster presentations at the conference, both on Friday, Nov. 14.Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported that for Q3 ended Sept. 30, 2014, its loss was narrower than expected, while revenue fell short of analysts' forecasts, despite improving 128% year over year. The biopharmaceutical company posted Q3 net loss of $10.7 million, or $0.05 per share, compared with the prior-year period's $17.2 million or $0.08 loss per share. Revenue was $8.16 million, up from $3.58 million in the same quarter last year. Analysts polled by Capital IQ were expecting a loss of $0.12 per share on revenues of $10.83 million. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares are trading with a 52-week range of $3.26 - $7.97.Myriad Genetics, Inc. (NASDAQ:MYGN) said has expanded an agreement with AbbVie, Inc. (ABBV) to use its Tumor BRACAnalysis CD as a companion diagnostic in support of AbbVie's poly polymerase or PARP inhibitor, veliparib. The collaboration builds upon Myriad's previous agreements with AbbVie under which the company is providing BRACAnalysis CDx testing to support several of AbbVie's ongoing Phase 3 clinical studies of veliparib, including neo-adjuvant and metastatic breast cancer. "Myriad's goal is to provide best-in-class patient care, and we believe that Tumor BRACAnalysis CDx will help us deliver on this goal by identifying patients who may respond to breakthrough therapies currently in development," said Peter Meldrum, president and CEO of Myriad Genetics, Inc. (NASDAQ:MYGN).